BACKGROUND: Upper gastrointestinal disease has become an important aspect in the management of patients with familial adenomatous polyposis (FAP). METHODS: A review of the literature was carried out using Medline. Epidemiology, pathology and treatment options are considered. RESULTS AND CONCLUSION: Despite the fact that over 90 per cent of patients with FAP develop duodenal adenomas, only 5 per cent go on to develop cancer. In the absence of methods to detect who is at risk of cancer, all patients undergo regular endoscopic surveillance at present. Chemoprevention in the form of drug therapy may be the answer to controlling the disease.
BACKGROUND: Upper gastrointestinal disease has become an important aspect in the management of patients with familial adenomatous polyposis (FAP). METHODS: A review of the literature was carried out using Medline. Epidemiology, pathology and treatment options are considered. RESULTS AND CONCLUSION: Despite the fact that over 90 per cent of patients with FAP develop duodenal adenomas, only 5 per cent go on to develop cancer. In the absence of methods to detect who is at risk of cancer, all patients undergo regular endoscopic surveillance at present. Chemoprevention in the form of drug therapy may be the answer to controlling the disease.
Authors: M B Farnell; G H Sakorafas; M G Sarr; C M Rowland; G G Tsiotos; D R Farley; D M Nagorney Journal: J Gastrointest Surg Date: 2000 Jan-Feb Impact factor: 3.452
Authors: Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt Journal: Am J Gastroenterol Date: 2015-02-03 Impact factor: 10.864
Authors: Paul Hasty; Carolina B Livi; Sherry G Dodds; Diane Jones; Randy Strong; Martin Javors; Kathleen E Fischer; Lauren Sloane; Kruthi Murthy; Gene Hubbard; Lishi Sun; Vincent Hurez; Tyler J Curiel; Zelton Dave Sharp Journal: Cancer Prev Res (Phila) Date: 2013-11-26
Authors: Paul Tescher; Finlay A Macrae; Tony Speer; Damien Stella; Robert Gibson; Jason A Tye-Din; Geeta Srivatsa; Ian T Jones; Kaye Marion Journal: Hered Cancer Clin Pract Date: 2010-04-04 Impact factor: 2.857